1. What conditions has Pyridoxal phosphate been studied for?

• Bone and tooth mineralization disorders (hypophosphatasia and low alkaline phosphatase states): PLP is described as a biochemical substrate of tissue-nonspecific alkaline phosphatase (TNAP). In TNAP deficiency (hypophosphatasia), PLP accumulates.

• Cardiovascular calcification (CVC): TNAP is a proposed therapeutic target to limit vascular/valvular calcification; PLP is one of TNAP’s in vivo substrates, relevant to understanding consequences of TNAP inhibition.

• Neurotransmitter disorders, especially Aromatic L-amino acid decarboxylase (AADC) deficiency: AADC is a PLP-dependent enzyme; the study notes poor or no response in most patients to “pyridoxine derivatives,” but PLP biology is central to the disorder.

• Cancer metabolism:

  • Clear cell renal cell carcinoma (ccRCC): Tumors repress urea cycle enzymes; reduced ARG2 activity promotes tumor growth partly by conserving PLP.

  • Acute myeloid leukemia (AML): AML cells show dependency on PDXK (enzyme producing PLP from vitamin B6); blocking the B6→PLP pathway inhibits AML proliferation in preclinical models.

• Inherited metabolic diseases due to PLP-enzyme mutations: A review abstract lists multiple rare diseases (e.g., AADC deficiency, homocystinuria, primary hyperoxaluria type 1, X-linked sideroblastic anemia) where patients “can benefit” to varying degrees from pyridoxine (a PLP precursor), implicating PLP-related therapy.

• General enzymology and metabolism: PLP-dependent enzymes (e.g., aspartate aminotransferase) are studied extensively for catalytic mechanisms; this is foundational rather than a clinical indication.

2. Does it work in treating those conditions? Summarize the evidence.

• Hypophosphatasia / low ALP states: The studies reviewed here support PLP as a diagnostic/biochemical marker of low TNAP activity rather than a proven treatment. In a study of 42 adults with unexplained low ALP, ALP was inversely correlated with PLP (r = -0.51, p = 0.001), and 24% had PLP above the reference range; all of those carried an ALPL mutation. This supports PLP accumulation when TNAP is impaired, but does not show PLP supplementation treats the condition.

• AADC deficiency: The AADC deficiency abstract states most patients have “poor or no response” to conventional treatments including “pyridoxine derivatives,” suggesting limited effectiveness of B6/PLP-directed therapy for many patients. (It also highlights gene therapy as a more promising approach.)

• Other PLP-enzyme genetic diseases: A review abstract states that patients with several PLP-enzyme disorders “can benefit, although at different degrees, from the administration of pyridoxine,” and proposes PLP may help not only binding defects but also folding defects (a “chaperone” role). This is supportive but broad and not specific about magnitude of benefit, which conditions respond best, or clinical trial quality.

• Cancer (AML, ccRCC): The cancer studies do not support PLP as a treatment; rather, they suggest the opposite direction may be therapeutically relevant in some contexts. In AML, disrupting PDXK/PLP availability inhibited AML proliferation in preclinical work. In ccRCC, conserving PLP is described as one mechanism by which reduced ARG2 activity promotes tumor growth. These findings imply that increasing PLP could theoretically be undesirable in certain cancers, but they are not clinical supplementation trials.

• Cardiovascular calcification: The CVC abstract discusses TNAP inhibition as a strategy and notes TNAP’s role in PLP metabolism; it does not present evidence that PLP itself treats CVC.

3. What health benefits does it have?

• Essential cofactor for many enzymes and pathways: One abstract summarizes PLP’s coenzymatic roles across amino acid synthesis/interconversion/degradation, one-carbon unit replenishment, biogenic amine (neurotransmitter) metabolism, tetrapyrrole synthesis, and amino-sugar metabolism.

• Supports neurotransmitter production (indirectly): The cardiovascular calcification review notes TNAP participates in PLP metabolism and “the production of neurotransmitters,” reflecting PLP’s centrality to neurochemistry.

• Potential “chemical chaperone” effect in some genetic enzyme defects: The PLP-enzyme review describes evidence that PLP can aid refolding in vitro for some PLP-enzymes and may improve folding efficiency of misfolded variants; clinically, some patients with PLP-enzyme disorders can benefit from pyridoxine (a precursor).

• Oxidative stress protection (non-human evidence): A vitamin B6 review notes vitamin B6/PLP functions as a singlet oxygen scavenger and has protective effects against oxidative stress in fungi. This suggests antioxidant potential, but the study does not establish human clinical benefit.

4. Does it have any downsides or side effects?

• Biochemical accumulation in TNAP deficiency (marker of disease): In low ALP/hypophosphatasia contexts, PLP accumulates because TNAP dephosphorylates PLP. The adult low-ALP study found higher PLP levels strongly associated with ALPL mutations (p < 0.0001). This is not a “side effect” of supplementation per se, but it indicates that elevated PLP can reflect impaired metabolism and may coexist with calcified tissue issues (e.g., tooth loss was more common in mutation carriers: 48% vs 12%).

• Potential concern in some cancers (mechanistic/preclinical): In ccRCC, conserving PLP is described as supporting tumor growth; in AML, blocking PLP production inhibits proliferation. These do not prove PLP supplementation worsens cancer outcomes, but they raise a plausible theoretical downside in certain malignancies based on tumor metabolic dependencies.

• Limited efficacy in AADC deficiency: The AADC deficiency abstract reports poor/no response to pyridoxine derivatives in most patients, which is a practical downside (lack of benefit) rather than a toxicity signal.

• Evidence limitations: The studies reviewed here do not report specific adverse event rates or classic vitamin B6 toxicity outcomes; therefore, side effects of PLP supplementation cannot be characterized from these studies alone.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

• ALPL (TNAP) variants and PLP accumulation (diagnostic relevance; possible supplementation implications): In the study of 42 adults with unexplained low ALP, 50% carried ALPL mutations (mostly heterozygous missense). Mutation carriers had higher PLP (p < 0.0001) and PEA (p < 0.0001), and 24% had PLP above reference range—all of whom carried a mutated allele. This indicates genotype strongly influences PLP levels. While the study does not test PLP treatment, it suggests that individuals with ALPL mutations already have elevated PLP due to reduced dephosphorylation, so supplementation could be unnecessary or complicating without medical supervision.

• DDC variants (AADC deficiency) and response to B6/PLP-related therapy: The AADC deficiency abstract catalogs 82 DDC variants and notes most patients have poor/no response to conventional treatments including pyridoxine derivatives. This implies genotype may limit responsiveness to B6-based approaches, though the study does not map specific variants to responders.

• PLP-enzyme gene mutations where pyridoxine may help (variable responsiveness): A review abstract states that patients with mutations in genes encoding PLP-enzymes can benefit to varying degrees from pyridoxine, including cases where mutations cause folding defects (suggesting a pharmacogenomic “rescue” mechanism). However, it does not specify which variants predict response, and evidence strength likely varies by disease and mutation.

• PDXK dependency in AML (tumor genomics rather than inherited pharmacogenomics): The AML abstract identifies PDXK as an AML-selective dependency; pharmacologic blockade of the B6→PLP pathway inhibited AML proliferation in preclinical models. This is more relevant to precision oncology (targeting a metabolic dependency) than to predicting benefit from PLP supplementation.

Understanding the Role of Vitamin B6 in Health

Overview

The research text emphasizes the significance of the B vitamin family in maintaining mitochondrial function and preventing mitochondrial toxicity. B vitamins, including Pyridoxal (B6), act as coenzymes crucial for cellular enzymes and one-carbon metabolism.

Vitamin B6 and One-Carbon Metabolism

Vitamin B6, along with folic acid, B12, and B2, is integral to one-carbon metabolism, facilitating the transfer of carbon units essential for DNA synthesis and methylation processes.

Health Implications and Deficiencies

Deficiencies in B vitamins, including B6, can impair mitochondrial function, while supplementation can alleviate symptoms and prevent toxicity. B vitamins also serve as antioxidants to combat oxidative stress. Elevated homocysteine levels, potentially regulated by B6, are associated with cardiovascular disease and cognitive disorders.

Research on Aging Populations

The research indicates growing interest in B vitamins due to their potential links to diseases prevalent in aging populations, such as cognitive decline, Alzheimer's disease, cardiovascular disease, and cancer.

Lung Cancer Risk and Vitamin B6

An observational study, the VITamins And Lifestyle (VITAL) cohort, found that high-dose vitamin B6 supplements were associated with an increased risk of lung cancer in men, particularly smokers. This suggests that caution should be exercised with high-dose B6 supplementation.

Conclusion

While B vitamins, including B6, play a crucial role in cellular metabolism and disease prevention, their supplementation should be carefully considered, especially in high doses or specific populations.

References:

1. Mitochondrial function and toxicity: role of the B vitamin family on mitochondrial energy metabolism
2. Folate, vitamin B12 and vitamin B6 and one carbon metabolism
3. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention
4. Long-Term, Supplemental, One-Carbon Metabolism-Related Vitamin B Use in Relation to Lung Cancer Risk in the Vitamins and Lifestyle (VITAL) Cohort
5. VITamins And Lifestyle cohort study: study design and characteristics of supplement users
6. Folate and colorectal cancer: an evidence-based critical review
7. The effects of long-term daily folic acid and vitamin B12 supplementation on genome-wide DNA methylation in elderly subjects
8. One-Carbon Metabolism in Prostate Cancer: The Role of Androgen Signaling
9. Alkaline phosphatase: Structure, expression and its function in bone mineralization.
   Selvaraj Vimalraj (2020) - Gene
10. TNAP as a therapeutic target for cardiovascular calcification: a discussion of its pleiotropic functions in the body.
    Claudia Goettsch, Agnieszka Strzelecka-Kiliszek, Laurence Bessueille, Thibaut Quillard, Laura Mechtouff, Slawomir Pikula, Emmanuelle Canet-Soulas, Jose Luis Millan, Caroline Fonta, David Magne (2022) - Cardiovascular research
11. Peroxisomal Metabolite and Cofactor Transport in Humans.
    Serhii Chornyi, Lodewijk IJlst, Carlo W T van Roermund, Ronald J A Wanders, Hans R Waterham (2020) - Frontiers in cell and developmental biology
12. Aspartate aminotransferase: an old dog teaches new tricks.
    Michael D Toney (2014) - Archives of biochemistry and biophysics
13. Arginase 2 Suppresses Renal Carcinoma Progression via Biosynthetic Cofactor Pyridoxal Phosphate Depletion and Increased Polyamine Toxicity.
    Joshua D Ochocki, Sanika Khare, Markus Hess, Daniel Ackerman, Bo Qiu, Jennie I Daisak, Andrew J Worth, Nan Lin, Pearl Lee, Hong Xie, Bo Li, Bradley Wubbenhorst, Tobi G Maguire, Katherine L Nathanson, James C Alwine, Ian A Blair, Itzhak Nissim, Brian Keith, M Celeste Simon (2018) - Cell metabolism
14. Clinical, biochemical and genetic spectrum of low alkaline phosphatase levels in adults.
    Leyre Riancho-Zarrabeitia, Mayte García-Unzueta, Jair A Tenorio, Juan A Gómez-Gerique, Víctor L Ruiz Pérez, Karen E Heath, Pablo Lapunzina, José A Riancho (2016) - European journal of internal medicine
15. Aromatic amino acid decarboxylase deficiency: Molecular and metabolic basis and therapeutic outlook.
    Nastassja Himmelreich, Riccardo Montioli, Mariarita Bertoldi, Carla Carducci, Vincenzo Leuzzi, Corinne Gemperle, Todd Berner, Keith Hyland, Beat Thöny, Georg F Hoffmann, Carla B Voltattorni, Nenad Blau (2019) - Molecular genetics and metabolism
16. Vitamin B6 Addiction in Acute Myeloid Leukemia.
    Chi-Chao Chen, Bo Li, Scott E Millman, Cynthia Chen, Xiang Li, John P Morris, Allison Mayle, Yu-Jui Ho, Evangelia Loizou, Hui Liu, Weige Qin, Hardik Shah, Sara Violante, Justin R Cross, Scott W Lowe, Lingbo Zhang (2020) - Cancer cell
17. The chaperone role of the pyridoxal 5'-phosphate and its implications for rare diseases involving B6-dependent enzymes.
    Barbara Cellini, Riccardo Montioli, Elisa Oppici, Alessandra Astegno, Carla Borri Voltattorni (2014) - Clinical biochemistry
18. Edodin: A New Type of Toxin from Shiitake Mushroom (
    Lucía Citores, Sara Ragucci, Claudia C Gay, Rosita Russo, Angela Chambery, Antimo Di Maro, Rosario Iglesias, José M Ferreras (2024) - Toxins
19. Pyridoxal phosphate: biosynthesis and catabolism.
    Tathagata Mukherjee, Jeremiah Hanes, Ivo Tews, Steven E Ealick, Tadhg P Begley (2011) - Biochimica et biophysica acta
20. Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitor.
    Jing Zhao, Yuhong Du, John R Horton, Anup K Upadhyay, Bin Lou, Yan Bai, Xing Zhang, Lupei Du, Minyong Li, Binghe Wang, Lixin Zhang, Joseph T Barbieri, Fadlo R Khuri, Xiaodong Cheng, Haian Fu (2011) - Proceedings of the National Academy of Sciences of the United States of America
21. Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors.
    Peter Kenneth Gillman (2011) - Journal of clinical psychopharmacology
22. The impact of dietary changes and dietary supplements on lipid profile.
    Jingbo Huang, Jiri Frohlich, Andrew P Ignaszewski (2011) - The Canadian journal of cardiology
23. The relationship between plasma albumin, alkaline phosphatase and pyridoxal phosphate concentrations in plasma and red cells: Implications for assessing vitamin B6 status.
    Dinesh Talwar, Anthony Catchpole, John M Wadsworth, Barry J Toole, Donald C McMillan (2020) - Clinical nutrition (Edinburgh, Scotland)
24. The Affinity of Carboplatin to B-Vitamins and Nucleobases.
    Beata Szefler, Przemysław Czeleń, Przemysław Krawczyk (2021) - International journal of molecular sciences
25. Prediction of all-cause mortality by B group vitamin status in the elderly.
    Yi-Chen Huang, Meei-Shyuan Lee, Mark L Wahlqvist (2012) - Clinical nutrition (Edinburgh, Scotland)
26. Structural basis for dysregulation of aminolevulinic acid synthase in human disease.
    Jessica L Taylor, Breann L Brown (2022) - The Journal of biological chemistry
27. Insight into vitamin B
    Lorena Tremiño, Alicia Forcada-Nadal, Vicente Rubio (2018) - Human mutation
28. Current knowledge for pyridoxine-dependent epilepsy: a 2016 update.
    Izabella Agostinho Pena, Alex MacKenzie, Clara D M Van Karnebeek (2017) - Expert review of endocrinology & metabolism

Upload Whole Genome Sequencing (WGS) raw DNA data today and take a deep dive into your genome!

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Or if you only have standard microarray data currently, upload raw DNA data to get started with your free DNA raw data analysis today!